Tarsus Pharmaceuticals, Inc. (TARS)

Market Cap	1.78B
Revenue (ttm)	129.62M
Net Income (ttm)	-134.34M
Shares Out	38.23M
EPS (ttm)	-3.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,019
Open	46.90
Previous Close	46.89
Day's Range	45.78 - 47.37
52-Week Range	15.60 - 52.99
Beta	1.00
Analysts	Strong Buy
Price Target	54.20 (+16.36%)
Earnings Date	Nov 13, 2024

About TARS

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to addr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 244
• Stock Exchange: NASDAQ
• Ticker Symbol: TARS
• Website: https://www.tarsusrx.com

Financial Performance

In 2023, Tarsus Pharmaceuticals's revenue was $17.45 million, a decrease of -32.42% compared to the previous year's $25.82 million. Losses were -$135.89 million, 118.9% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is $54.2, which is an increase of 16.36% from the latest price.

Price Target

$54.2

(16.36% upside)

Analyst Consensus: Strong Buy